Oliver Y Tang1, Ross A Clarke2, Krissia M Rivera Perla2,3, Kiara M Corcoran Ruiz2, Steven A Toms2,4, Robert J Weil5. 1. The Warren Alpert Medical School of Brown University, Providence, RI, USA. oliver_tang@brown.edu. 2. The Warren Alpert Medical School of Brown University, Providence, RI, USA. 3. Harvard T.H Chan School of Public Health, Boston, MA, USA. 4. Department of Neurosurgery, Rhode Island Hospital, Providence, RI, USA. 5. Southcoast Brain & Spine, Southcoast Health, Dartmouth, MA, USA.
Abstract
INTRODUCTION: Dual-eligible (DE) patients, simultaneous Medicare and Medicaid beneficiaries, have been shown to have poorer clinical outcomes while incurring higher resource utilization. However, neurosurgical oncology outcomes for DE patients are poorly characterized. Accordingly, we examined the impact of DE status on perioperative outcomes following glioma, meningioma, or metastasis resection. METHODS: We identified all admissions undergoing a craniotomy for glioma, meningioma, or metastasis resection in the National Inpatient Sample from 2002 to 2011. Assessed outcomes included inpatient mortality, complications, discharge disposition, length of stay (LOS), and hospital costs. Multivariable regression adjusting for 13 patient, severity, and hospital characteristics assessed the association between DE status and outcomes, relative to four reference insurance groups (Medicare-only, Medicaid-only, private insurance, self-pay). RESULTS: Of 195,725 total admissions analyzed, 3.0% were dual-eligible beneficiaries (n = 5933). DEs were younger than Medicare admissions (P < 0.001) but older than Medicaid, private, and self-pay admissions (P < 0.001). Relative to other insurance groups, DEs also exhibited higher severity of illness, risk of mortality, and Charlson Comorbidity Index scores as well as treatment at low-volume hospitals (all P < 0.001). DEs had lower mortality than self-pay admissions (odds ratio [OR] 0.47, P = 0.017). Compared to Medicare, Medicaid, private, and self-pay admissions, DEs had lower rates of discharge disposition (OR 0.53, 0.50, 0.34, and 0.27, respectively, all P < 0.001). DEs also had higher complications (OR 1.23 and 1.20, respectively, both P < 0.05) and LOS (β = 1.06 and 1.13, respectively, both P < 0.01) than Medicare and private insurance beneficiaries. Differences in discharge disposition remained significant for all three tumor subtypes, but only glioma DE admissions continued to exhibit higher complications and LOS. CONCLUSIONS: DEs undergoing definitive craniotomy for brain tumor had higher rates of unfavorable discharge disposition compared to all other insurance groups and, especially for glioma surgery, had higher inpatient complication rates and LOS. Practice and policy reforms to improve outcomes for this vulnerable clinical population are warranted.
INTRODUCTION: Dual-eligible (DE) patients, simultaneous Medicare and Medicaid beneficiaries, have been shown to have poorer clinical outcomes while incurring higher resource utilization. However, neurosurgical oncology outcomes for DE patients are poorly characterized. Accordingly, we examined the impact of DE status on perioperative outcomes following glioma, meningioma, or metastasis resection. METHODS: We identified all admissions undergoing a craniotomy for glioma, meningioma, or metastasis resection in the National Inpatient Sample from 2002 to 2011. Assessed outcomes included inpatient mortality, complications, discharge disposition, length of stay (LOS), and hospital costs. Multivariable regression adjusting for 13 patient, severity, and hospital characteristics assessed the association between DE status and outcomes, relative to four reference insurance groups (Medicare-only, Medicaid-only, private insurance, self-pay). RESULTS: Of 195,725 total admissions analyzed, 3.0% were dual-eligible beneficiaries (n = 5933). DEs were younger than Medicare admissions (P < 0.001) but older than Medicaid, private, and self-pay admissions (P < 0.001). Relative to other insurance groups, DEs also exhibited higher severity of illness, risk of mortality, and Charlson Comorbidity Index scores as well as treatment at low-volume hospitals (all P < 0.001). DEs had lower mortality than self-pay admissions (odds ratio [OR] 0.47, P = 0.017). Compared to Medicare, Medicaid, private, and self-pay admissions, DEs had lower rates of discharge disposition (OR 0.53, 0.50, 0.34, and 0.27, respectively, all P < 0.001). DEs also had higher complications (OR 1.23 and 1.20, respectively, both P < 0.05) and LOS (β = 1.06 and 1.13, respectively, both P < 0.01) than Medicare and private insurance beneficiaries. Differences in discharge disposition remained significant for all three tumor subtypes, but only glioma DE admissions continued to exhibit higher complications and LOS. CONCLUSIONS: DEs undergoing definitive craniotomy for brain tumor had higher rates of unfavorable discharge disposition compared to all other insurance groups and, especially for glioma surgery, had higher inpatient complication rates and LOS. Practice and policy reforms to improve outcomes for this vulnerable clinical population are warranted.
Keywords:
Glioma; Health policy; Hospital complications; Hospital costs; Meningioma; Metastasis; National Inpatient Sample; Social determinants of health; Socioeconomic status
Authors: Ankush Chandra; Jonathan W Rick; Cecilia Dalle Ore; Darryl Lau; Alan T Nguyen; Diego Carrera; Alexander Bonte; Annette M Molinaro; Philip V Theodosopoulos; Michael W McDermott; Mitchel S Berger; Manish K Aghi Journal: Neurosurg Focus Date: 2018-06 Impact factor: 4.047
Authors: Kerry A Vaughan; Christian Lopez Ramos; Vivek P Buch; Rania A Mekary; Julia R Amundson; Meghal Shah; Abbas Rattani; Michael C Dewan; Kee B Park Journal: J Neurosurg Date: 2018-09-01 Impact factor: 5.115
Authors: Rahul A Sastry; Nathan J Pertsch; Oliver Tang; Belinda Shao; Steven A Toms; Robert J Weil Journal: J Clin Neurosci Date: 2020-10-02 Impact factor: 1.961
Authors: David J Cote; Quinn T Ostrom; Haley Gittleman; Kelsey R Duncan; Travis S CreveCoeur; Carol Kruchko; Timothy R Smith; Meir J Stampfer; Jill S Barnholtz-Sloan Journal: Cancer Date: 2019-06-17 Impact factor: 6.860
Authors: Brett E Youngerman; Alfred I Neugut; Jingyan Yang; Dawn L Hershman; Jason D Wright; Jeffrey N Bruce Journal: J Neurooncol Date: 2017-11-14 Impact factor: 4.130
Authors: Erica C Leifheit; Yun Wang; George Howard; Virginia J Howard; Larry B Goldstein; Thomas G Brott; Judith H Lichtman Journal: Neurology Date: 2018-09-28 Impact factor: 11.800